The studies described in this report were performed to determine, whether it is possible to produce live virus vaccines without serum or fractions thereof used during any cell or virus passage, thus completely serum-free. Two viruses were included in the experiments: Bovine Herpesvirus 1 (BHV-1) and Bovine Parainfluenza type 3 virus (PI3). Both viruses were found to grow to satisfactory titers, and to be stable after freeze-drying and subsequent storage at temperatures of 14 8C and 220 8C for at least one year. Moreover, a vaccine containing serum free produced BHV-1 was tested in a vaccination-challenge experiment. For comparison, a vaccine batch with BHV-1 grown in serum-containing cell culture medium was included in the study. Both vaccine preparations performed equally well and both met the strict requirements as laid down in the European Phamacopeia. Moreover, in two separate experiments the safety of serum-free produced BHV-1 and PI3 after overdose and repeated administration even in very young calves and even after four administrations has been demonstrated. This report is the first, which to our knowledge demonstrates the safety and efficacy of serum-free produced live vaccines in the target animal as well as the stability of these products.
Introduction
contamination with BVDV (Bolin et al. 1991; Wessman and Levings 1998) and to inactivate the raw Adventitious viruses originating from the use of animaterials e.g. by g-irradiation (House et al. 1990 ; mal derived compounds during cell and / or virus Kurth et al. 1999; Reid 1998) . However, a recent culture have been detected in a number of biological outbreak of BVDV after vaccination with a contamiproducts (Kappeler et al. 1996; Harasawa 1995;  nated live vaccine (Falcone et al. 2000) demonstrates Harasawa and Tomiyama 1994; O'Toole et al. 1994;  the practical relevance of the problem. Rabenau et al. 1993; Kreeft et al. 1990; Senda et al. The use of serum-free culture media (Froud 1999; 1995; Harasawa and Sasaki 1995) . Among these Merten 1999) is a different approach to avoid conexamples, bovine viral diarrhea virus (BVDV) is the tamination of biologicals with adventitious agents. most common contaminant and bovine serum is the Following this approach, we have developed a most common source of contamination. This is due to serum-free production process for live attenuated the capacity of BVDV to spread transplacentally and vaccines for active immunization of cattle with the subsequently infect the immunologically immature bovine herpesvirus type 1 (BHV-1) and bovine fetus (Moennig and Liess 1995) . Intensive efforts are parainfluenza type 3 virus (PI3). The production made to improve the testing of raw materials for method for both viruses entails a completely serum-free (no serum or fractions thereof) growth of cells second virus was first neutralised by incubation with a (20 passages) and virus (5 passages) including serummonospecific neutralising antiserum. free cryopreservation of the cell substrate.
For commercial use of such a product three main Testing the stability of freeze-dried BHV-1 and PI3 requirements have to be fulfilled: (i) the serum-free produced viruses must retain their infectivity after Three batches of freeze-dried SF-BHV-1 / PI3 were freeze-drying and subsequent storage, (ii) the vaccine subjected to real time stability testing. Vials were has to be efficacious and (iii) the application of the stored at 14 8C and 220 8C during 15 months. The product may not have any negative effect on the vaccine virus titers were determined and compared vaccinates. Serum-free produced BHV-1 and PI3 have with the titers measured before storage. been tested for these criteria. For comparison, virus grown with FCS was included in some of the studies.
BHV-1 vaccination-challenge trial
Eighteen calves aged between three and four months and devoid of BHV-1 neutralising (VN) antibodies Materials and methods were randomly allocated to 3 groups of 6 calves. The mean daily clinical scores per group were calcusupplemented with the antibiotics neomycin (50 mg / lated. ml) and polymyxin B (50 mg/ml). 
Both, SF and FCS , vaccine virus suspensions
Determination of virus shedding were blended with the same freeze drying stabiliser, which contains sugars, amino acids and low molecuBoth nasal cavities were swabbed using cotton-tipped lar weight peptides in a phosphate buffer and were plastic swabs and the content adhering to the cotton freeze-dried using the identical programme. The same tip extracted into 1.0 ml of PBS. accompanying solvent was used for reconstitution and Titrations of BHV-1 infectivity were performed in (where applicable) dilution.
monolayers of BEL cells grown in 96-well microtitraThe BHV-1 challenge was performed with a field tion plates using 200 ml / well and 4 wells per dilution. isolate passaged twice on bovine embryonic lung cells Cytopathic effects were read 3 to 5 days later. The (BEL). mean tissue culture infective dose was calculated by a Virus titration and serum neutralisation tests (VN) standard method (Kaerber 1931 ) and titres are exwere performed on BEL cells cultured in Welcome pressed per ml of medium. MEM supplemented with 5% fetal calf serum and the antibiotics penicillin (100 units / ml), and strepNeutralising antibody titres tomycin (100 mg / ml). The cells were incubated at 37 8C in a humidified atmosphere with 5% CO . For Titration of BHV-1 neutralising antibodies involved a 1 virus mixtures were incubated at 37 8C for 2 hours for FCS -BHV-1 (8.2-8.4 log TCID / 2 ml vial).
10 50 before the cells were added. Titres were expressed as For PI3 live virus titres after freeze drying are 8.4-9.0 the reciprocal of the highest serum dilution that log TCID / 2 ml vial (SF and FCS1).
10 50 caused complete neutralisation. Titers determined before and after storage of SF-BHV-1 / PI3 at 148 and 220 8C are given in Table 1 .
Safety studies with SF-BHV-1 /PI3 and SF-BHV-1
There was no significant difference between the titers in calves measured before or after storage up to 15 months at the indicated temperatures (p , 0.05, LSD t-test). Six colostrum deprived calves aged between 2-3
These data indicate, that freeze-dried SF-BHV-1 and weeks were vaccinated IN with an overdose of SF-SF-PI3 are stable under normal storage conditions for BHV-1 and SF-PI3 and another six colostrum defreeze dried live vaccines. prived calves of the same age were injected intramuscularly with the same virus preparation. Two
Efficacy of SF-BHV-1 in a vaccination-challenge weeks thereafter, vaccination was repeated with a trial single dose according to the same route as the first vaccination. Each vaccinated group was housed together with three additional colostrum deprived calves Clinical signs and body temperatures after and that served as unvaccinated controls.
challenge virus infection In a separate study, ten BHV-1 seronegative calves Typical clinical signs of respiratory disease such as aged between five and six months were vaccinated IN coughing, sneezing, nasal and ocular discharge, inand intramuscularly (IM) four times at fortnightly creased and accentuated breathing were seen in the intervals with an 80x overdose of SF-BHV-1 in a 2 ml unvaccinated animals after challenge infection with volume.
wild type BHV-1. These reactions were classified as In both studies, animals were observed for systemic mild to moderate. The unvaccinated animals were the and local clinical reactions and their rectal body most severely affected by the challenge infection. temperatures were measured daily until three weeks This is reflected by the sum of daily clinical scores per after the repeated vaccination (SF-BHV-1 / PI3 study) group (see Figure 1a ). The differences in the total of or two weeks after the fourth inoculation (SF-BHV-1 clinical scores between both vaccinated groups and study).
the control group were highly significant (p , 0.05).
One of the characteristics of BHV-1 infection is pyrexia. All unvaccinated animals showed a dramatic Results increase in body temperature above to 40.0 8C between 4-10 days post infection (see Figure 1b for Virus yields and stability of freeze-dried SF-BHV-1 course of mean temperatures, individual data not and SF-PI3 shown). In contrast, only one animal from each vaccinated group had a temperature above 40.0 8C for one Typical live virus yields obtained in large scale proday, specifically 40.2 8C in the SF-BHV-1 group and 2 1 duction (.100 roller bottles of 1750 cm per lot) for 40.1 8C in the FCS BHV group. The differences in SF-BHV-1 after freeze drying are 8.4-8.6 log rectal temperatures on post infection days 4-10 be-10 TCID / 2 ml vial which is comparable to the yields tween the vaccinated groups and the control group 50 Figure 1a . Clinical scores before and after challenge. s: SF-BHV-1 vaccinated group; v: FCS BHV-1 vaccinated group; 3: unvaccinated group. Clinical parameters were scored 0 when normal, 1 when mild, 2 when moderate and 3 when markedly abnormal. The scores for each parameter and animal were summed up to give the daily score per group (n56 animals per group) (Makoschey and Keil 2000).
were highly significant (p , 0.05) indicating that the Safety of SF-BHV-1 /PI3 and SF-BHV-1 after animals were well protected against pyrexia.
overdose and repeated vaccination
Virus shedding after vaccination and challenge
Following overdose and repeated vaccination with There was no vaccine virus recovered from any of the SF-BHV-1 / PI3 or inoculation of 80-times the proteccontrol group calves. The replication of vaccinal tive dose of SF-BHV-1 no clinical reactions attributinocula was closely similar in animals of both vaccine able to the vaccine viruses were observed. Moreover, groups. Both vaccines replicated for 7 to 8 days with no swelling was seen during the daily observation of peak recovery (about 5.0 to 6.0 log TCID / ml) in the intramuscular injection sites. The respective re-10 50 most animals between days 4 and 5, data not shown). gions of the necks of the calves were never painful nor All unvaccinated animals excreted challenge virus hot at palpation at any time in any animal. to peak titers of at least 8.2 log TCID per swab for OnecalfvaccinatedintramuscularlywithSF-BHV-1 / 10 50 one or several days (individual data not shown). The PI3 had an elevated temperature (40.2 8C) at four maximum titers of all vaccinated animals were at least days after vaccination. Upon antibiotic treatment, the 100-times lower than this value. The mean titers of temperature dropped. By the next day, the temperashed virus are presented in Figure 2 . Furthermore, the ture was within the physiological range (39.3 8C), average number of days on which virus was excreted indicating that the rise in temperature was caused by was considerably reduced (7 days in the vaccinates a bacterial infection rather than the vaccination. and 11 days in the controls). The differences in total Two animals vaccinated with SF-BHV-1 had a challenge virus excretion between the two vaccinated slightly elevated temperature (39.9 8C) and one groups and the unvaccinated control group were animal had a clearly elevated temperature (40.3 8C) highly significant (p , 0.05).
only at the first vaccination. All other temperatures measured in both studies requirements for efficacy and safety in the target were within the physiological range.
animal.
The results of a vaccination -challenge trial performed as prescribed in the monograph for live BHV-1 vaccines of the European Pharmacopoeia are shown.
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Discussion
The SF-BHV-1 vaccine and the FCS BHV-1 vaccine performed equally well with respect to reduction of The present studies were performed to establish both clinical disease as well as challenge virus whether completely serum-free produced BHV-1 and excretion and both met the strict requirements of the PI3 viruses are suitable for incorporation in commermonograph. Similar studies have been performed cial live vaccines for cattle. The production method with SF-PI3 which proofs to be efficacious as for both viruses entails a completely serum-free (no vaccine virus as well (data not shown). These data serum or fractions thereof) growth of cells (20 confirm that the efficacy of a live virus vaccine is passages) and virus (5 passages) including serumdetermined exclusively by the live virus titre and not free cryopreservation of the cell substrate.
by the composition of the growth medium. The results described in this report demonstrate,
The mechanisms underlying the growth promoting that fetal calf serum or compounds thereof are not activity of fetal calf serum and the individual active always required to (a) grow viruses to sufficiently components are still not completely understood. high titers, (b) retain virus infectivity after freezeHowever, it has been demonstrated that serum can drying and (c) after long time storage at 220 8C or successfully be replaced by hormones (Wu and Sato 14 8C, which are normal storage conditions for 1978; Mather and Sato 1979; Taub et al. 1979 ) and freeze-dried live vaccines. Besides these in vitro plant extracts (Merten et al. 1999) . The use of serum characteristics, a live vaccine needs to fulfill in vivo free and even protein free media gets more and more common especially in the field of production of produced vaccine is the exclusion of any risk of recombinant proteins in insect cell cultures, Chinese contamination with adventitious viruses that may be hamster ovary cells and hybridoma cells (Cruz et al. present in components of animal origin. Since any 1998; Yoshinari and Matsumoto 1998). More recentinfectious agent present in fetal calf serum by nature ly, Kessler et al. (1998) reported the production of an is infectious for cattle, this approach is extremely inactivated influenza virus antigen under serum-free advantageous in live vaccines for cattle. The list of conditions. In this study a serum-free product was cattle viruses detected in fetal calf serum includes tested for haemagglutinin and neuraminidase ac-BVDV (Harasawa 1995) , bovine polyomavirus tivities but alas no efficacy data were reported.
( Kappeler et al. 1996) and Bluetongue virus A general point of concern regarding the use of (O'Toole et al. 1994) . Even if fetal calf serum fetal calf serum in the production of vaccines is that batches are extensively tested, one will always it may cause local or systemic adverse reactions.
depend on the detection limit of the respective test Immunological studies on patients with serum-sicksystem and can only detect known pathogens. As the ness like reactions after rabies vaccination revealed research in diseases of cattle progresses there will that these individuals possessed IgE antibodies to probably be new emerging diseases and infectious FCS (Warrington et al. 1987) agents. Also the validation of methods used for the We have demonstrated, that viruses produced inactivation of fetal calf serum is limited by the without serum or fractions thereof are safe upon detection limit for testing of residual infectivity. overdose and repeated administration even in very Moreover, it can only be done for known pathogens young animals or after 4-times administration. and the experiences with transmissible enTherefore the use of the vaccines in the target cephalopathies (Prusiner 1991) teaches that there species can confidently be recommended without may be completely new forms of infectious agents. reservations.
The recent outbreak of BVDV after vaccination However, the major advantage of a serum-free with a contaminated live vaccine (Falcone et al. 1999 . 
